6Tavassoli FA, Devilee P, World Health Organization. Pathology and genetics of tumours of the breast and female genital organs [ M]. Lyon: IARC press,2003:24.
1Sφdie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci USA, 2001, 98(19): 10869- 10874.
2Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1 ) : 4429 - 4434.
3West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles[ J ].Proc Natl Acad Sci USA, 2001, 98(20): 11462- 11467.
4Abd E1-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses[J], Int J Cancer, 2005, 116(3):340-350.
5Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immtmofluorescence and immunohistochemical analysis [ J ]. Breast Cancer Res Treat, 2008, 110(2): 245-256.
6Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16): 5367-5374.
8Lenna E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) [J]. Mod Pathol, 2007, 20(11): 1200-1207.
9Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1) : 25 - 32.
10Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecttlar subtypes respond differently to preoperative chemotherapy [ J ]. Clin Cancer Res, 2005,11(16) : 5678 - 5685.
